JP2023549067A5 - - Google Patents
Info
- Publication number
- JP2023549067A5 JP2023549067A5 JP2023525485A JP2023525485A JP2023549067A5 JP 2023549067 A5 JP2023549067 A5 JP 2023549067A5 JP 2023525485 A JP2023525485 A JP 2023525485A JP 2023525485 A JP2023525485 A JP 2023525485A JP 2023549067 A5 JP2023549067 A5 JP 2023549067A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cov
- sars
- spike protein
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2017058.5 | 2020-10-27 | ||
| GBGB2017058.5A GB202017058D0 (en) | 2020-10-27 | 2020-10-27 | Antibodies and uses thereof |
| PCT/EP2021/079901 WO2022090353A1 (en) | 2020-10-27 | 2021-10-27 | Antibodies against sars-cov-2 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549067A JP2023549067A (ja) | 2023-11-22 |
| JP2023549067A5 true JP2023549067A5 (enExample) | 2024-11-05 |
Family
ID=73727037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525485A Pending JP2023549067A (ja) | 2020-10-27 | 2021-10-27 | Ｓａｒｓ－ｃｏｖ－２に対する抗体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250026813A1 (enExample) |
| EP (1) | EP4237442A1 (enExample) |
| JP (1) | JP2023549067A (enExample) |
| KR (1) | KR20230113295A (enExample) |
| CN (1) | CN117396501A (enExample) |
| AU (1) | AU2021369450A1 (enExample) |
| CA (1) | CA3199594A1 (enExample) |
| CO (1) | CO2023006684A2 (enExample) |
| GB (1) | GB202017058D0 (enExample) |
| IL (1) | IL302244A (enExample) |
| MX (1) | MX2023004869A (enExample) |
| WO (1) | WO2022090353A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| AU2021252164B2 (en) | 2020-04-09 | 2026-07-02 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| MX2022014598A (es) | 2020-05-26 | 2023-03-31 | Regeneron Pharma | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. |
| CR20220660A (es) | 2020-06-03 | 2023-02-17 | Regeneron Pharma | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 |
| CN114989263B (zh) * | 2021-03-01 | 2023-07-25 | 中国医学科学院基础医学研究所 | 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用 |
| CN114989255B (zh) * | 2021-03-01 | 2023-07-25 | 中国医学科学院基础医学研究所 | 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用 |
| EP4370210A1 (en) | 2021-07-14 | 2024-05-22 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| CN121002058A (zh) * | 2022-12-09 | 2025-11-21 | 艾布维兹生物公司 | 针对SARS-CoV-2及其变体的抗体或其片段 |
| CN120981481A (zh) * | 2023-01-10 | 2025-11-18 | 萨那生物技术股份有限公司 | Cd19特异性抗体构建体以及它们的组合物 |
| KR20250016745A (ko) * | 2023-07-25 | 2025-02-04 | 연세대학교 산학협력단 | 신규한 펩타이드, 이를 포함하는 항체 또는 이의 항원 결합 단편, 이를 포함하는 SARS-CoV-2 검출용 물질 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| ES2198922T3 (es) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | Particulas porosas grandes emitadas por un inhalador. |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
-
2020
- 2020-10-27 GB GBGB2017058.5A patent/GB202017058D0/en not_active Ceased
-
2021
- 2021-10-27 JP JP2023525485A patent/JP2023549067A/ja active Pending
- 2021-10-27 KR KR1020237017200A patent/KR20230113295A/ko active Pending
- 2021-10-27 WO PCT/EP2021/079901 patent/WO2022090353A1/en not_active Ceased
- 2021-10-27 EP EP21805859.2A patent/EP4237442A1/en active Pending
- 2021-10-27 CA CA3199594A patent/CA3199594A1/en active Pending
- 2021-10-27 IL IL302244A patent/IL302244A/en unknown
- 2021-10-27 US US18/250,716 patent/US20250026813A1/en active Pending
- 2021-10-27 MX MX2023004869A patent/MX2023004869A/es unknown
- 2021-10-27 CN CN202180085791.0A patent/CN117396501A/zh active Pending
- 2021-10-27 AU AU2021369450A patent/AU2021369450A1/en not_active Abandoned
-
2023
- 2023-05-23 CO CONC2023/0006684A patent/CO2023006684A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102184343B1 (ko) | 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법 | |
| DK2807192T3 (en) | COMPOSITION AND PROCEDURE FOR DIAGNOSTICATION AND TREATMENT OF DISEASES RELATED TO NEURITE DEGENERATION | |
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2021521843A (ja) | 最適化された抗ｔｌ１ａ抗体 | |
| CN118141914A (zh) | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 | |
| KR20150094621A (ko) | 스타필로코커스 아우레우스 표면 결정인자에 대한 항체 | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| TW202334429A (zh) | Sars-cov-2棘蛋白特異性抗體及其用途 | |
| IL262441B2 (en) | Methods for treating diseases in which il-13 activity is harmful using antibodies to il-13 | |
| WO2023129928A2 (en) | Antibody specific to spike protein of sars-cov-2 and uses thereof | |
| JP2017507131A5 (enExample) | ||
| JP2025507595A5 (enExample) | ||
| CN118696061A (zh) | Nectin细胞黏附分子4之特异性抗体及其用途 | |
| WO2022228183A1 (zh) | 抗siglec15抗体及其制备方法和用途 | |
| CN116178530A (zh) | 抗体在治疗SARS-CoV-2感染的用途 | |
| US10689441B2 (en) | Anti—TLR4 antibodies and methods of use thereof | |
| KR20180105642A (ko) | 위암의 검출 및 치료를 위한 조성물 및 방법 | |
| TW202214297A (zh) | 用於治療疼痛之結合TGF-α及表皮調節素(EPIREGULIN)之抗體 | |
| CN104797597A (zh) | 针对胞壁肽的单克隆抗体 | |
| JP2022527790A5 (enExample) | ||
| US20170038381A1 (en) | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders | |
| CN112996540A (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| JP2024543911A5 (enExample) | ||
| WO2024020582A1 (en) | Therapeutic neutralizing antibodies for sars-cov-2 | |
| EP3619536A1 (en) | Methods of selectively treating asthma using il-17 antagonists |